8-K: Kewaunee Scientific Reports Mixed Results for First Quarter of Fiscal Year 2025

Kewaunee Scientific's first quarter of fiscal year 2025 saw a slight decrease in sales and earnings compared to the prior year, with international sales impacted by project delays in India.

Summary

• Kewaunee Scientific Corporation reported a 2.9% decrease in sales for the first quarter of fiscal year 2025, with sales totaling $48.393 million compared to $49.839 million in the same quarter last year.
• Pre-tax earnings decreased by 28.8% to $2.430 million, down from $3.412 million in the prior year quarter.
• Net earnings also saw a decrease, coming in at $2.193 million compared to $2.474 million in the first quarter of the previous year.
• EBITDA for the quarter was $3.325 million, a decrease from $4.305 million in the prior year quarter.
• Diluted earnings per share were $0.74, down from $0.86 in the prior year quarter.
• The company's order backlog increased to $159.4 million on July 31, 2024, compared to $140.8 million on July 31, 2023, and $155.6 million on April 30, 2024.
• Domestic sales increased slightly by 0.3% to $35.523 million, while international sales decreased by 10.7% to $12.870 million due to construction site delays in India.
• The company's total cash on hand was $25.186 million on July 31, 2024, compared to $25.938 million on April 30, 2024.
• Working capital was $56.012 million, compared to $49.291 million at the end of the first quarter last year and $56.037 million on April 30, 2024.
• The company's debt-to-equity ratio was 0.68-to-1 on July 31, 2024, compared to 0.70-to-1 on April 30, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to the mixed results. While the backlog is strong, the decrease in sales and earnings, particularly in the international segment, is concerning. The company's forward-looking statements are positive, but the current performance is not strong.

Positives

• The company's order backlog increased to $159.4 million, indicating strong future demand.
• Domestic segment sales increased slightly by 0.3% and domestic segment net earnings increased to $2.871 million from $2.711 million in the prior year quarter.
• Working capital increased to $56.012 million from $49.291 million at the end of the first quarter last year.
• The company's debt-to-equity ratio decreased slightly to 0.68-to-1 from 0.70-to-1 on April 30, 2024.

Negatives

• Overall sales decreased by 2.9% compared to the same quarter last year.
• Pre-tax earnings decreased by 28.8% year-over-year.
• Net earnings decreased to $2.193 million from $2.474 million in the prior year quarter.
• International sales decreased by 10.7% due to customer construction site delays in India.
• Corporate segment pre-tax net loss increased to $1.992 million from $1.004 million in the prior year quarter.
• EBITDA decreased to $3.325 million from $4.305 million in the prior year quarter.

Risks

• The company faces risks related to international operations, particularly construction site delays in India which impacted sales.
• Fluctuations in operating results from quarter to quarter pose a risk to the company's financial performance.
• Changes in raw materials and commodity costs could impact profitability.
• The company is exposed to competitive and general economic conditions, including supply disruptions.
• The company is exposed to risks related to changes in customer demands and required delivery schedules.

Future Outlook

The company's backlog remains strong and quoting for new projects remains high, providing a line of sight to another strong year for the company.

Management Comments

• Our financial performance for the first quarter of fiscal year 2025 was solid.
• Domestic segment operating performance was improved when compared to last year's first quarter as our manufacturing loadings remain at a consistent level.
• Site delays in India on multiple projects impacted our ability to ship products and deliver services leading to a slightly down quarter when compared to the prior year first quarter.
• Looking ahead, our backlog remains strong and quoting for new projects remains high, providing a line of sight to another strong year for the Company.

Industry Context

The results reflect a mixed performance in the laboratory and technical furniture industry, with domestic demand remaining stable but international operations facing challenges. The company's strong backlog suggests continued demand for its products, but the impact of project delays in India highlights the risks associated with international operations.

Comparison to Industry Standards

• Kewaunee's performance is mixed when compared to industry peers. While the company's backlog growth is a positive sign, the decrease in sales and earnings is concerning.
• Companies like Hamilton Scientific and Thermo Fisher Scientific, which also operate in the laboratory furniture and equipment space, have shown varying results in recent quarters, with some experiencing growth while others face similar challenges in supply chain and project delays.
• Kewaunee's domestic segment performance is in line with expectations for stable demand in the US market, but the international segment's struggles highlight the challenges of managing global projects.
• The company's debt-to-equity ratio of 0.68-to-1 is within a reasonable range for the industry, but the decrease in profitability could put pressure on this metric in future quarters.

Stakeholder Impact

• Shareholders may be concerned about the decrease in earnings and sales.
• Employees may be impacted by the company's performance, particularly in the international segment.
• Customers may experience delays in project delivery due to construction site issues in India.
• Suppliers may be affected by changes in the company's production and delivery schedules.

Key Dates

Keywords

laboratory furniture, healthcare furniture, technical furniture, EBITDA, sales, earnings, backlog, debt-to-equity, Kewaunee Scientific, financial results